News

The 2023 Association for Research in Vision and Ophthalmology (ARVO) annual meeting promises to provide numerous opportunities to meet up with old friends and colleagues and forge relationships with new ones as well as enhance future research and practice endeavors.

The study compared eyes with retinopathy of prematurity (ROP) that were treated with laser and age-matched control eyes without ROP.

The spherical equivalent was significantly more myopic in the eyes treated with laser in a recent study.

The Association for Research in Vision and Ophthalmology (ARVO) 2023 annual meeting is convening in New Orleans from April 23 to 27 at the Ernest N. Morial Convention Center. The theme of the Annual Meeting speaks both to the mechanistic diversity in ocular disease in addition to the diversity of vision scientists who are from multiple backgrounds and perspectives.

Esen Akpek, MD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss ocular surface disease and the lifestyle choices that could affect eye health. As well as what The Tear Film & Ocular Surface Society is doing to promote research on the topic.

A research team of scientists from a trio of European universities, led by a Northumbria University academic, has received funding to research age-related macular degeneration.

A research team made up of scientists from a trio of European universities and led by a Northumbria University academic, has received funding to research age-related macular degeneration.

Patients and employees, past and present, have had personal and protected health information acquired without authorization.

Researchers conducted clinical imaging and histopathologic studies to gain a better understanding of geographic atrophy (GA) in 3 siblings.

If no comment from the FDA is received within 30 days, the company said it will initiate the BRM424 phase 2 study in the first half of 2023.

According to data, 62% of patients treated with teprotumumab-trbw had a clinically meaningful improvement in proptosis at Week 24compared with 25% of patients receiving placebo.

The atropine drops did not cause significant changes in the near vision or the pupillary size, according to study investigators.

The ESSENCE-2 study showed a significantly greater reduction in the total corneal fluorescein staining (tCFS) score.

One way to advance the current understanding of GA is to study how disease progression varies among related individuals.

A team of researchers has uncovered a mechanism that causes blindness, could lead to targeted therapies.

According to National Eye Institute researchers, the variants generate malformed proteins that alter the stability of the membrane attack complex, which may drive a chronic inflammatory response in the retina.

According to National Eye Institute researchers, the variants generate malformed proteins that alter the stability of the membrane attack complex, which may drive a chronic inflammatory response in the retina.

A study shows Atropine 0.01% eye drops decreased myopia progression in children over the course of 1 year.

Ophthalmologists can learn the latest techniques to help patients like Tommy Pham from the New York Mets during the first annual IKA Keratoconus Symposium: Front to Back and Everything In Between, taking place April 22-23 in Scottsdale, Arizona.

Eye rubbing is a common practice, but one that can cause a number of problems.

Eyenuk Inc. founder and CEO Kaushal Solanki, PhD, went from working for the Defense Department to founding a company with a focus on artificial intelligence for ophthalmology. Find out what led him to make that jump.

The Eye Rubbing Cycle Study yields cautions for patients with keratoconus and ocular surface disease.

HuidaGene Therapeutics’ HG004 receives ODD for inherited retinal disease caused by RPE65 mutations.

By crossing into the retina, investigators have uncovered a new DHA supplement achieves what previous ones could not.

Intimate partner violence awareness in ophthalmologists can be heightened thanks to a recent study.

Alice Epitropoulos, MD, goes over some tips and methods to educate patients about OSD before performing any surgery.

No clinically relevant or dose-limiting adverse events were identified after repeated intravitreal injections.